Rigel says two of its lead product candidates R548 and R333 enters into ... pharmabiz.com The company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The second candidate, R333, is a topical JAK/SYK inhibitor aimed at treating various phases of discoid ... |
